Atherosclerosis
Volume 212, Issue 1 , Pages 55-62 , September 2010

Heart rate reduction with ivabradine improves erectile dysfunction in parallel to decrease in atherosclerotic plaque load in ApoE-knockout mice

Received 25 June 2009 ,Revised 22 February 2010 ,Accepted 2 March 2010.

References 

  1. Bohm M, Baumhakel M, Probstfield JL, et al. Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomised AssessmeNT Study in ACE-INtolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND). American Heart Journal. 2007;154:94–101
  2. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. The Journal of Urology. 1994;151:54–61
  3. Solomon H, Man JW, Jackson G. Erectile dysfunction and the cardiovascular patient: endothelial dysfunction is the common denominator. Heart. 2003;89:251–253
  4. Baumhakel M, Bohm M. Erectile dysfunction correlates with left ventricular function and precedes cardiovascular events in cardiovascular high-risk patients. International Journal of Clinical Practice. 2007;61:361–366
  5. Kirby M, Jackson G, Betteridge J, Friedli K. Is erectile dysfunction a marker for cardiovascular disease?. International Journal of Clinical Practice. 2001;55:614–618
  6. Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996–3002
  7. Kannel WB, Kannel C, Paffenbarger RS, Cupples LA. Heart rate and cardiovascular mortality: the Framingham Study. American Heart Journal. 1987;113:1489–1494
  8. Diaz A, Bourassa MG, Guertin MC, Tardif JC. Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease. European Heart Journal. 2005;26:967–974
  9. Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease and left ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet. 2008;372:807–816
  10. Skantze HB, Kaplan J, Pettersson K, et al. Psychosocial stress causes endothelial injury in cynomolgus monkeys via beta 1-adrenoceptor activation. Atherosclerosis. 1998;136:153–161
  11. DiFrancesco D. Cardiac pacemaker I(f) current and its inhibition by heart rate-reducing agents. Current Medical Research and Opinion. 2005;21:1115–1122
  12. Colin P, Ghaleh B, Monnet X, et al. Contributions of heart rate and contractility to myocardial oxygen balance during exercise. American Journal of Physiology. 2003;284:H676–H682
  13. Custodis F, Baumhakel M, Schlimmer N, et al. Heart rate reduction by ivabradine reduces oxidative stress, improves endothelial function, and prevents atherosclerosis in apolipoprotein E-deficient mice. Circulation. 2008;117:2377–2387
  14. Xie D, Odronic SI, Wu F, et al. A mouse model of hypercholesterolemia-induced erectile dysfunction. The Journal of Sexual Medicine. 2007;4:898–907
  15. Behr-Roussel D, Darblade B, Oudot A, et al. Erectile dysfunction in hypercholesterolemic atherosclerotic apolipoprotein E knockout mice. The Journal of Sexual Medicine. 2006;3:596–603
  16. Baumhaekel M, Schlimmer N, Buyukafsar K, Arikan O, Boehm M. Nebivolol, but not Metoprolol improves endothelial function of the corpus cavernosum in ApoE-knockout-mice. The Journal of Pharmacology and Experimental Therapeutics. 2008;
  17. Buyukafsar K, Un I. Effects of the Rho-kinase inhibitors, Y-27632 and fasudil, on the corpus cavernosum from diabetic mice. European Journal of Pharmacology. 2003;472:235–238
  18. Baumhakel M, Custodis F, Schlimmer N, Laufs U, Bohm M. Improvement of endothelial function of the corpus cavernosum in apolipoprotein E knockout mice treated with irbesartan. The Journal of Pharmacology and Experimental Therapeutics. 2008;327:692–698
  19. Laufs U, Wassmann S, Czech T, et al. Physical inactivity increases oxidative stress, endothelial dysfunction, and atherosclerosis. Arteriosclerosis, Thrombosis and Vascular Biology. 2005;25:809–814
  20. Yavuzgil O, Altay B, Zoghi M, et al. Endothelial function in patients with vasculogenic erectile dysfunction. International Journal of Cardiology. 2005;103:19–26
  21. Feldman HA, Johannes CB, Derby CA, et al. Erectile dysfunction and coronary risk factors: prospective results from the Massachusetts male aging study. Preventive Medicine. 2000;30:328–338
  22. Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. The Journal of Clinical Investigation. 1997;100:2153–2157
  23. Beere PA, Glagov S, Zarins CK. Retarding effect of lowered heart rate on coronary atherosclerosis. Science. 1984;226:180–182New York, N.Y
  24. Reil JC, Bohm M. The role of heart rate in the development of cardiovascular disease. Clinical Research in Cardiology. 2007;96:585–592
  25. Drouin A, Gendron ME, Thorin E, et al. Chronic heart rate reduction by ivabradine prevents endothelial dysfunction in dyslipidaemic mice. British Journal of Pharmacology. 2008;154:749–757
  26. Reil JC, Bohm M. BEAUTIFUL results–the slower, the better?. Lancet. 2008;372:779–780
  27. Baumhakel M, Schlimmer N, Bohm M. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. International Journal of Impotence Research. 2008;20:493–500
  28. Bassiouny HS, Zarins CK, Kadowaki MH, Glagov S. Hemodynamic stress and experimental aortoiliac atherosclerosis. Journal of Vascular Surgery. 1994;19:426–434
  29. Burnett AL, Musicki B, Jin L, Bivalacqua TJ. Nitric oxide/redox-based signalling as a therapeutic target for penile disorders. Expert Opinion on Therapeutic Targets. 2006;10:445–457

PII: S0021-9150(10)00184-X

doi: 10.1016/j.atherosclerosis.2010.03.002

Atherosclerosis
Volume 212, Issue 1 , Pages 55-62 , September 2010

Article Tools

* Image Usage & Resolution